{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndécane-3 : Questions médicales les plus fréquentes",
"headline": "Syndécane-3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndécane-3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-30",
"dateModified": "2025-04-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndécane-3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Syndécanes",
"url": "https://questionsmedicales.fr/mesh/D053667",
"about": {
"@type": "MedicalCondition",
"name": "Syndécanes",
"code": {
"@type": "MedicalCode",
"code": "D053667",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.550.847"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndécane-3",
"alternateName": "Syndecan-3",
"code": {
"@type": "MedicalCode",
"code": "D053670",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Addolorata Pisconti",
"url": "https://questionsmedicales.fr/author/Addolorata%20Pisconti",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, IIB, University of Liverpool, Liverpool, UK."
}
},
{
"@type": "Person",
"name": "Martin Götte",
"url": "https://questionsmedicales.fr/author/Martin%20G%C3%B6tte",
"affiliation": {
"@type": "Organization",
"name": "Department of Gynecology and Obstetrics, Münster University Hospital, Albert-Schweitzer-Campus 1, D11, 48149 Muenster, Germany."
}
},
{
"@type": "Person",
"name": "Ilona Kovalszky",
"url": "https://questionsmedicales.fr/author/Ilona%20Kovalszky",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary."
}
},
{
"@type": "Person",
"name": "Samantha Arokiasamy",
"url": "https://questionsmedicales.fr/author/Samantha%20Arokiasamy",
"affiliation": {
"@type": "Organization",
"name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom."
}
},
{
"@type": "Person",
"name": "James R Whiteford",
"url": "https://questionsmedicales.fr/author/James%20R%20Whiteford",
"affiliation": {
"@type": "Organization",
"name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion.",
"datePublished": "2022-08-03",
"url": "https://questionsmedicales.fr/article/35922515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41586-022-05006-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Promoting physical activity for people with haemophilia in the age of new treatments.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35896000",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/hae.14641"
}
},
{
"@type": "ScholarlyArticle",
"name": "The promoting/inhibiting effect of water vapor on the selective catalytic reduction of NO",
"datePublished": "2022-07-22",
"url": "https://questionsmedicales.fr/article/35907283",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jhazmat.2022.129665"
}
},
{
"@type": "ScholarlyArticle",
"name": "Price Promotions of E-Liquid Products Sold in Online Stores.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35886722",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph19148870"
}
},
{
"@type": "ScholarlyArticle",
"name": "Strategies to Promote Cognitive Health in Aging: Recent Evidence and Innovations.",
"datePublished": "2022-07-15",
"url": "https://questionsmedicales.fr/article/35835897",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11920-022-01348-x"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycoprotéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008562"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndécanes",
"item": "https://questionsmedicales.fr/mesh/D053667"
},
{
"@type": "ListItem",
"position": 7,
"name": "Syndécane-3",
"item": "https://questionsmedicales.fr/mesh/D053670"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndécane-3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndécane-3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndécane-3",
"description": "Comment diagnostiquer une anomalie du syndécane-3 ?\nQuels examens sont utilisés pour évaluer le syndécane-3 ?\nLe dosage sanguin peut-il aider au diagnostic ?\nQuels marqueurs sont associés au syndécane-3 ?\nLe diagnostic est-il difficile à établir ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Anaphase-Promoting+Complex-Cyclosome&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndécane-3",
"description": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?\nLe syndécane-3 est-il lié à des maladies spécifiques ?\nPeut-on observer des symptômes cutanés ?\nY a-t-il des symptômes systémiques associés ?\nLes symptômes varient-ils d'un patient à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Anaphase-Promoting+Complex-Cyclosome&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndécane-3",
"description": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?\nY a-t-il des facteurs de risque connus ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation influence-t-elle le syndécane-3 ?\nLe stress a-t-il un impact sur le syndécane-3 ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Anaphase-Promoting+Complex-Cyclosome&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndécane-3",
"description": "Quels traitements ciblent le syndécane-3 ?\nLe traitement est-il efficace ?\nY a-t-il des effets secondaires des traitements ?\nDes traitements expérimentaux existent-ils ?\nLe suivi est-il nécessaire après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Anaphase-Promoting+Complex-Cyclosome&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndécane-3",
"description": "Quelles complications peuvent survenir avec le syndécane-3 ?\nLe syndécane-3 est-il lié à des complications cardiovasculaires ?\nDes complications neurologiques sont-elles possibles ?\nComment gérer les complications liées au syndécane-3 ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Anaphase-Promoting+Complex-Cyclosome&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndécane-3",
"description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il les risques ?\nLes infections jouent-elles un rôle ?\nY a-t-il un lien avec l'obésité ?\nLes facteurs environnementaux sont-ils significatifs ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Anaphase-Promoting+Complex-Cyclosome&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie du syndécane-3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses de tissus pour évaluer l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer le syndécane-3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies et des analyses immunohistochimiques peuvent être réalisées pour évaluer le syndécane-3."
}
},
{
"@type": "Question",
"name": "Le dosage sanguin peut-il aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de dosage sanguin standardisé pour le syndécane-3."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés au syndécane-3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux et des cytokines peuvent être associés à l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Le diagnostic est-il difficile à établir ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic peut être complexe en raison de la variabilité de l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles de l'adhésion cellulaire et des anomalies tissulaires."
}
},
{
"@type": "Question",
"name": "Le syndécane-3 est-il lié à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est impliqué dans des maladies comme le cancer et les maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent survenir en raison de l'implication du syndécane-3 dans la peau."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes systémiques comme la fatigue et la douleur peuvent être observés dans certains cas."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier considérablement selon l'individu et la pathologie associée."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme l'inflammation chronique et des prédispositions génétiques sont identifiés."
}
},
{
"@type": "Question",
"name": "Des dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être recommandés pour les personnes à risque élevé de maladies associées."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le syndécane-3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer positivement l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le syndécane-3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affecter l'expression du syndécane-3 et contribuer à des maladies."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent le syndécane-3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des anticorps monoclonaux peuvent être utilisés pour cibler le syndécane-3."
}
},
{
"@type": "Question",
"name": "Le traitement est-il efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité du traitement dépend de la pathologie et de l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires comme des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Des traitements expérimentaux existent-ils ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour cibler le syndécane-3."
}
},
{
"@type": "Question",
"name": "Le suivi est-il nécessaire après traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour évaluer la réponse au traitement et ajuster si nécessaire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le syndécane-3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des métastases tumorales et des troubles immunitaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le syndécane-3 est-il lié à des complications cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre le syndécane-3 et des complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines recherches indiquent que des complications neurologiques peuvent être associées."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au syndécane-3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et les maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les infections jouent-elles un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections chroniques peuvent augmenter le risque de dysfonction du syndécane-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec l'obésité ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est un facteur de risque reconnu pour des dysfonctionnements associés au syndécane-3."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des polluants environnementaux peut influencer l'expression du syndécane-3."
}
}
]
}
]
}
Haemophilia treatment has seen great advances in recent years with an accompanied reduced risk of physical activity (PA) related bleeds. Based on its known health benefits, people with haemophilia (PW...
Retailer price promotions are an important marketing strategy to attract consumers. However, there is scarce evidence on how retail price promotions are being implemented by e-cigarette online stores,...
We collect data on e-liquid price-promotion activities from online stores using web scraping. From February to May 2021, we scraped the price promotion data of over 14,000 e-liquid products, from five...
Of the 14,000 e-liquid products and over, 13,326 (92.36%) were on sale, and each online store on average offered discounts from 9.20% to 47.53% for these products. The distribution of the after-discou...
Despite low prices, price promotions are common for e-liquid products, which may undermine the effect of e-cigarette pricing policies such as excise tax that are designed to raise e-cigarette prices....
We review recent work on applications of non-pharmacologic strategies to promote cognitive health in older adulthood and discuss potential network mechanisms, limitations, and considerations for impro...
In healthy older adults and patients with mild cognitive impairment, cognitive training produces global and domain-specific cognitive gains, though effect sizes tend to be modest and transfer is varia...
In-depth knowledge of liver regeneration could facilitate the development of therapies for liver injury and liver failure. As a member of the homeobox superfamily, HOXA13 plays an important role in re...
Forkhead box S1 (FOXS1) is a member of the forkhead box (FOX) transcriptional factor superfamily. The biological roles and underlying regulatory mechanism of FOXS1 in CRC remain unclear....
Bioinformatics analysis, Western blotting, real-time PCR, and immunohistochemistry (IHC) were used to detect the expression FOXS1 in CRC. MTT assay, transwell assay, human umbilical vein endothelial c...
The results showed that FOXS1 expression was upregulated in CRC tissues compared with adjacent normal intestine tissues. A high FOXS1 expression is positively correlated with poor survival. FOXS1 prom...
The results suggest that FOXS1 promotes angiogenesis and metastasis by upregulating CXCL8 in CRC. Interference with the FOXS1/CXCL8 axis may serve as a potential therapeutic target for the treatment o...
Cervical cancer has been recognized as the second most common cancer in women worldwide. Previous studies have reported that some circular RNAs (circRNAs) can influence the progression of cervical can...
RT-qPCR and western blot assays were used to detect the expression and protein levels. Mechanism experiments were conducted to investigate the relationship among circ_0060551, TPD52, miR-520a-5p and E...
According to the results, circ_0060551 was upregulated in cervical cancer cells and could promote the migration and invasion of cells via TPD52. In addition, circ_0060551 could up-regulate TPD52 expre...
Our study proved that circ_0060551 could promote the migration and invasion of cervical cancer cells....
The concept of biological identity has been traditionally a central issue in immunology. The assumption that entities foreign to a specific organism should be rejected by its immune system, while self...
Melanoma is the most aggressive and life-threatening form of skin cancer. Key molecular events underlying the melanocytic transformation into malignant melanoma mainly involve gene mutations in which ...